首页> 外文期刊>Applied immunohistochemistry and molecular morphology: AIMM >The Use of Cytokeratin 19 (CK19) Immunohistochemistry In Lesions of the Pancreas, Gastrointestinal Tract, and Liver
【24h】

The Use of Cytokeratin 19 (CK19) Immunohistochemistry In Lesions of the Pancreas, Gastrointestinal Tract, and Liver

机译:细胞角蛋白19(CK19)免疫组织化学在胰腺,胃肠道和肝脏病变中的应用

获取原文
获取原文并翻译 | 示例
           

摘要

Cytokeratin immunostaining forms the bedrock of the immunohistochemical evaluation of tumors. Cytokeratin 19 (CK19) belongs to a family of keratins, which are normally expressed in the lining of the gastroenteropancreatic and hepatobiliary tracts. CK19 immunohistochemistry has been used successfully in thyroid tumors to recognize papillary carcinomas for some time. However, its use in the pancreas, liver, and gastrointestinal tract (GIT) has only recently come to the fore. The purpose of this review is to look at the use of CK19 immunohistochemistry in tumors occurring at these sites. CK19 has been shown to be an independent prognostic factor for pancreatic neuroendocrine tumors, especially the insulin-negative tumors. CK19 positive tumors are associated with poor outcome irrespective of the established pathologic parameters such as size, mitoses, lymphovascular invasion, and necrosis.
机译:细胞角蛋白免疫染色形成了肿瘤免疫组织化学评估的基础。细胞角蛋白19(CK19)属于角蛋白家族,通常在胃肠胰和肝胆道的内膜中表达。 CK19免疫组化已成功用于甲状腺肿瘤中以识别乳头状癌。但是,它在胰腺,肝脏和胃肠道(GIT)中的使用才刚刚出现。这篇综述的目的是研究CK19免疫组织化学在这些部位发生的肿瘤中的应用。 CK19已被证明是胰腺神经内分泌肿瘤,特别是胰岛素阴性肿瘤的独立预后因素。 CK19阳性肿瘤与不良预后相关,而与已建立的病理参数(例如大小,有丝分裂,淋巴血管浸润和坏死)无关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号